Posted by bleauberry on June 27, 2018, at 6:38:14
My personal experience with SJW is that when/if it kicks in - for me that was in the 3-5 week range - the anti-depressive effect didn't have the numbing effect of SSRIs, but was more natural and open with a general feeling of contentment and re-engagement in life.
The other thing I have learned from personal experience (years ago) is that you can generate some serious Herxheimer reactions with it. A Herx (for short) is a die-off reaction of pathogenic microbes that causes a systemic inflammation response resulting in depression, anxiety, pain and fatigue. This is maybe one of the most accurate ways to diagnose a hidden case of Lyme - see if you can generate a Herx - because a healthy person won't be able to - a Lyme person will generate a Herx very easily.
Studies indicate that SJW has enough power as an antibiotic, anti fungal, and especially antiviral, to deal with prescription-resistant strains. I didn't know years ago it was a Herx - I thought SJW was just making me worse - but then when it kicked in it was pretty amazing. No prescription ever did that in all the years that followed. Wouldn't you know it, a psychiatrist got pissed at me for using SJW, actually yelled at me and lectured me, forced me to stop SJW, not happy I was doing much better, and then I crashed badly after that, and crashed even worse when that doc put me on Serzone instead. What a joke. Sick joke.
I'm thinking of maybe re-visiting SJW in terms of Lyme rather than in terms of mood. It is a powerful anti-microbial, anti-inflammatory, anti-pain, anti-cancer, neuroprotective, with mood lifting and anti-anxiety properties.
Efficacy of Hypericum extract WS(®) 5570 compared with paroxetine in patients with a moderate major depressive episode - a subgroup analysis.
Seifritz E1, Hatzinger M2, Holsboer-Trachsler E3.
Author information
Abstract
OBJECTIVES:
efficacy and tolerability of WS(®) 5570 for the treatment of acute mild-to-moderate depression, has been demonstrated in various studies. Here, we present a subgroup analysis of a double blind, randomised trial to compare the therapeutic efficacy of WS(®) 5570 with paroxetine in patients suffering from a major depressive episode with moderate symptom intensity.
METHODS:
moderate depression was defined by a baseline Hamilton Depression Rating Scale (HAM-D) total score between 22 and 25. Patients received, after a single blind placebo run-in phase of 3-7 d, either 3 × 300 mg/d WS(®) 5570 or 20 mg/d paroxetine for six weeks. The change of the HAM-D total score was used to describe the efficacy of WS(®) 5570 compared with paroxetine in the subgroup of patients with moderate depression.
RESULTS:
the reductions of the HAM-D total score were significantly more pronounced in patients treated with 3 × 300 mg/d WS(®) 5570 compared to 20 mg/d paroxetine.
CONCLUSIONS:
patients treated with WS(®) 5570 not only showed a reduction in depression severity score but also yielded greater response and remission rates compared with patients treated with paroxetine. Keypoints Various studies showed the efficacy and tolerability of WS(®) 5570 for the treatment of acute mild-to-moderate depression. Beneficial effects of WS(®) 5570 have been also shown in patients with moderate-to-severe depression. In this study reductions of the HAM-D total score were significantly more pronounced in patients with moderate depression treated with WS(®) 5570 compared with paroxetine. Patients treated with WS(®) 5570 not only showed a reduction in depression severity score but also yielded greater response and remission rates compared with patients treated with paroxetine.
poster:bleauberry
thread:1099311
URL: http://www.dr-bob.org/babble/20180521/msgs/1099311.html